Clearmind Medicine Inc. Common Shares
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It d… Read more
Clearmind Medicine Inc. Common Shares (CMND) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of October 2025: -1.078x
Based on the latest financial reports, Clearmind Medicine Inc. Common Shares (CMND) has a cash flow conversion efficiency ratio of -1.078x as of October 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.80 Million) by net assets ($1.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Clearmind Medicine Inc. Common Shares - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Clearmind Medicine Inc. Common Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Clearmind Medicine Inc. Common Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Clearmind Medicine Inc. Common Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Praetorian Acquisition Corp. Units
NASDAQ:PTORU
|
N/A |
|
140610
KO:140610
|
N/A |
|
Principal Real Estate Income Closed Fund
NYSE:PGZ
|
0.029x |
|
NAVCO Pharmaceuticals Inc.
F:F0U
|
N/A |
|
GRAND CITY PRO
BE:GYC
|
0.014x |
|
REBAB COMPANY
BC:REBAB-COMPANY
|
N/A |
|
Adriano Care SOCIMI SAU
MC:YADR
|
0.009x |
|
Sixt Leasing SE
STU:LNSX
|
-1.066x |
Annual Cash Flow Conversion Efficiency for Clearmind Medicine Inc. Common Shares (2014–2025)
The table below shows the annual cash flow conversion efficiency of Clearmind Medicine Inc. Common Shares from 2014 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-10-31 | $1.67 Million | $-6.64 Million | -3.970x | -153.91% |
| 2024-10-31 | $4.33 Million | $-6.76 Million | -1.564x | +75.60% |
| 2023-10-31 | $983.47K | $-6.30 Million | -6.407x | -290.27% |
| 2022-10-31 | $-1.50 Million | $-5.06 Million | 3.368x | +728.19% |
| 2021-10-31 | $3.87 Million | $-2.08 Million | -0.536x | -1.21% |
| 2020-10-31 | $374.78K | $-198.50K | -0.530x | -12.49% |
| 2019-10-31 | $101.63K | $-47.85K | -0.471x | -6.62% |
| 2018-10-31 | $182.24K | $-80.48K | -0.442x | -138.92% |
| 2017-10-31 | $49.36K | $-9.12K | -0.185x | -154.96% |
| 2016-10-31 | $-45.71K | $-15.37K | 0.336x | -81.84% |
| 2015-10-31 | $-21.49K | $-39.81K | 1.852x | +23.23% |
| 2014-10-31 | $-18.64K | $-28.01K | 1.503x | -- |